A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A diagnosis of relapsed CD20+ Follicular Lymphoma grade 1-3a
A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma
Evidence of progression or lack of response following at least 1 prior treatment
Able and willing to provide written informed consent and to comply with the study protocol
Disqualifiers
Known hypersensitivity to any study drug
Prior treatment with polatuzumab vedotin
Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies
Prior treatment with tafasitamab and/or lenalidomide
Trial design
Design model
Single group
Treatments tested in this trial
Mosunetuzumab
DrugGiven by IV (vein)
Polatuzumab vedotin
DrugGiven by IV (vein)
Tafasitamab
DrugGiven by IV (vein)
Lenalidomide
DrugGiven by PO
Treatment groups
36 Participants
are divided into 2 treatment groupsGroup A: Safety Run InExperimental treatment 4 interventions
Group B: Dose Expansion CohortExperimental treatment 4 interventions
Trial outcomes
Primary outcomes
1
The best overall response rate (ORR).
Time frame
through study completion; an average of 1 year.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov